Scinai Immunotherapeutics
SCNI
12 hedge funds and large institutions have $153K invested in Scinai Immunotherapeutics in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
14% less funds holding
Funds holding: 14 → 12 (-2)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
61% less capital invested
Capital invested by funds: $389K → $153K (-$236K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$13.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.71K |
| 3 |
Renaissance Technologies
New York
|
+$113 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$94.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$28K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13K |
| 4 |
Morgan Stanley
New York
|
-$12K |
| 5 |
TPWA
TRUE Private Wealth Advisors
Salem,
Oregon
|
-$9.57K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Envestnet Asset Management
Chicago,
Illinois
| $58K | -$94.8K | -842 | -52% |
|
|
TPWA
2
TRUE Private Wealth Advisors
Salem,
Oregon
| $34K | -$9.57K | -85 | -15% |
|
|
3
Morgan Stanley
New York
| $17K | -$12K | -107 | -32% |
|
|
4
Renaissance Technologies
New York
| $13K | +$113 | +1 | +0.5% |
|
5
Geode Capital Management
Boston,
Massachusetts
| $10K | – | – | – |
|
|
6
Millennium Management
New York
| $9K | +$13.8K | +123 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $6K | +$3.71K | +33 | +70% |
|
8
Credit Agricole
Montrouge Cedex,
France
| $3K | – | – | – |
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | – | – | – |
|
|
APC
10
Aspire Private Capital
Cornelius,
North Carolina
| $1K | – | – | – |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$28K | -238 | Closed |
|
|
12
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$13K | -111 | Closed |
|
13
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -10 | Closed |
|
SCNI Hedge Fund Activity: Q3 2022 in Review
12 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2022, worth a combined $153K — down 61% from $389K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SCNI and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $13.8K. The largest seller was Envestnet Asset Management, cutting an estimated $94.8K.
- 12 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2022, down from 14 in Q2 2022.
- Funds reported $153K of Scinai Immunotherapeutics stock for Q3 2022, down 61% quarter-over-quarter.
- 1 fund opened new Scinai Immunotherapeutics positions in Q3 2022 and 3 closed out, a net change of -2 holders.
- The largest Scinai Immunotherapeutics buyer in Q3 2022 was Millennium Management, an estimated $13.8K added.
- The largest Scinai Immunotherapeutics seller in Q3 2022 was Envestnet Asset Management, an estimated $94.8K sold.
Based on aggregated 13F filings for Q3 2022.